Tobias Weizel, Novocure’s General Manager Germany, leads the company’s commercial business in Germany and said he thrives off of the entrepreneurial, startup spirit inherent in Novocure.
“The company has grown substantially in the last several years, but we’ve managed to preserve this,” he said.
Tobias, who has a background of working in sales and marketing for biotech and pharmaceutical companies, joined Novocure in July 2016. Tobias said it can be challenging to get physicians to buy in to a different technology in order for it to become standard of care.
“We’ve made a great deal of advancement here, and we continue to increase education and exposure for key physicians,” he said.
Tobias said he and his team focus on educating physicians about Optune® because he believes German patients value the opinions of their doctors, especially when patients are facing a devastating disease like cancer.
It’s more than thinking outside of the box. There is no other company that does what we do – there’s no box we fit in, so we often have to create new ways of doing things.”
“These are the ones who tell their patients about Optune,” he said. “We continue to educate physicians on the benefits of this therapy and believe they will increasingly share this treatment option with their patients.”
Tobias believes that in order to be successful at Novocure, one has to have a passion for helping patients along with flexibility. With that flexibility, he said, comes the chance to define processes to move the company forward.
“It’s more than thinking outside of the box,” he said. “There is no other company that does what we do – there’s no box we fit in, so we often have to create new ways of doing things.”
Tobias said he feels energized by the opportunity to introduce a profoundly different therapy to patients and to change the way cancer is treated.
“I believe I’m really lucky,” he said. “Many companies in this industry say they put their patients first. For me, this is the first time that I actually feel it’s true.”
clinical trialsOur mechanism of action is broadly applicable across a variety of solid tumors.
publicationsWe have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.
novocuretrial.comThe science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.